Opus Genetics, Net Worth
Opus Genetics, Net Worth Breakdown | IRD |
Opus Genetics, Net Worth Analysis
Opus Genetics,'s net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Opus Genetics,'s financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Opus Genetics,'s overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Opus Genetics,'s net worth analysis. One common approach is to calculate Opus Genetics,'s market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Opus Genetics,'s stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Opus Genetics,'s net worth. This approach calculates the present value of Opus Genetics,'s future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Opus Genetics,'s cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Opus Genetics,'s net worth. This involves comparing Opus Genetics,'s financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Opus Genetics,'s net worth relative to its peers.
To determine if Opus Genetics, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Opus Genetics,'s net worth research are outlined below:
| Opus Genetics, may become a speculative penny stock | |
| Opus Genetics, had very high historical volatility over the last 90 days | |
| Opus Genetics, was previously known as OCUP Old and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with loss before taxes, overhead, and interest of (15.39 M). | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology 2025 Meeting |
Follow Opus Genetics,'s market capitalization trends
The company currently falls under 'Micro-Cap' category with a total capitalization of 35.67 M.Evaluate Opus Genetics,'s management efficiency
Opus Genetics, has Return on Asset of (0.3895) % which means that on every $100 spent on assets, it lost $0.3895. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.643) %, meaning that it generated no profit with money invested by stockholders. Opus Genetics,'s management efficiency ratios could be used to measure how well Opus Genetics, manages its routine affairs as well as how well it operates its assets and liabilities. As of March 19, 2025, Total Assets is expected to decline to about 40.3 M. Non Current Assets Total is expected to grow at the current pace this yearThe strategic initiatives led by Opus Genetics,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 0.1986 | Revenue | Quarterly Revenue Growth (0.68) | Revenue Per Share 0.337 | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Opus Genetics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Opus Genetics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Opus Genetics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Opus Genetics, time-series forecasting models is one of many Opus Genetics,'s stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Opus Genetics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Opus Genetics, Earnings per Share Projection vs Actual
Opus Genetics, Corporate Management
| Joseph MBA | Chief Officer | Profile | |
| Bernhard MBA | Senior Secretary | Profile | |
| Ashwath Jayagopal | Chief Officer | Profile | |
| Bindu Manne | Head Commercialization | Profile | |
| MAcc CPA | Senior Finance | Profile | |
| Nirav CFA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Opus Genetics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics,. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.09) | Revenue Per Share 0.337 | Quarterly Revenue Growth (0.68) | Return On Assets (0.39) | Return On Equity |
The market value of Opus Genetics, is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics,'s value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics,'s market value can be influenced by many factors that don't directly affect Opus Genetics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.